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INTRODUCTION— The American
Diabetes Association (ADA) standards of
care for diabetes state that statin therapy
should be initiated in individuals with di-
abetes and other cardiovascular risk fac-
torswithatargetLDLcholesterolof100
mg/dl. Furthermore, a possible target
LDL of 70 mg/dl is stated in patients
with diabetes and cardiovascular disease.
In this mini-review, we examine the evi-
dencethatexistsregardingLDLcholester-
ol–based treatment goals in individuals
withdiabetes.Fromourreviewofthecur-
rentliterature,itisevidentthatthemajor-
ity of clinical trials were designed using a
ﬁxed dose of statins and not in an LDL
cholesterol–based “treat-to-target” ap-
proach (thus differing from the common
design of blood glucose control trials).
This leads us to reassess the current
guidelines with special emphasis on the
very-low-risk and very-high-risk individ-
uals with diabetes, where the evidence is
less robust. We conclude that in this sub-
set of individuals with diabetes, statin
therapy should be based on the existing
evidence and prescribed in a ﬁxed-dose
manner.
P
ublished yearly, the ADA standards
of clinical care portray the principle
guidelines of diabetes care based on
the constantly evolving body of evidence
for the treatment of patients with diabe-
tes. The 2008 standards of care state the
following for statin use in diabetic indi-
viduals (1):
1) Statin therapy should be added to life-
style therapy, regardless of baseline
lipid levels, for diabetic patients a)
with overt cardiovascular disease
(CVD) (A: level of evidence as de-
scribed in the ADA evidence-grading
system [Table 1]); the primary goal is
anLDLcholesterol100mg/dl(2.6
mmol/l) (A); a lower LDL cholesterol
goal of 70 mg/dl (1.8 mmol/l), using a
high dose of a statin, is an option (E);
and b) without CVD who are over the
age of 40 years and have one or more
other CVD risk factor. The primary
goalisanLDLcholesterol100mg/dl
(2.6 mmol/l) (A).
2) For lower-risk patients than those
speciﬁed above (e.g., without overt
CVD and under the age of 40 years),
statin therapy should be considered in
addition to lifestyle therapy if LDL
cholesterol remains 100 mg/dl or in
individuals with multiple CVD risk
factors (E).
3) If drug-treated patients do not reach
theabovetargetsonmaximaltolerated
statintherapy,areductioninLDLcho-
lesterol of 40% from baseline is an
alternative therapeutic goal (A).
4) Combination therapy using statins
and other lipid-lowering agents may
be considered to achieve lipid targets
buthasnotbeenevaluatedinoutcome
studies for either CVD outcomes or
safety (E).
5) Statin therapy is contraindicated in
pregnancy (E).
Theseguidelinesarebasedonnumer-
oustrialsshowingabeneﬁtforstatinther-
apy both as primary and secondary
prevention of cardiovascular disease and
mortality(2–7).TrialsliketheCollaborative
Atorvastatin Diabetes Study (CARDS),
proved beyond doubt that patients with
type 2 diabetes and other risk factors for
CVD should be treated with a statin, ap-
parently disregarding their initial LDL
cholesterol level (5). However, most of
these trials did not set a goal LDL choles-
terol level for treatment but examined the
effect of a predetermined statin dose on
the outcome (2–5). Extrapolated from
these trials and from epidemiologic data
(8–11), a goal LDL of 100 mg% seems
adequate for the majority of patients. Yet
because of the problematic interpretation
of clinical trial data that was not inherent
initsbasicstructure,alternativetreatment
goalshavearisen,includingareductionof
LDL by 40% (in patients where LDL re-
duction could not reach the 100 mg%
goal) or a reduction below 70 mg% (in
very-high-risk patients—those with prior
cardiovascular disease or acute coronary
syndromes).
Some questions are raised from these
guidelines. First, the overall efﬁcacy of
statin use for primary prevention raises
the question who should not get a statin,
i.e., what is the evidence for their use as
primary prevention in diabetic individu-
als. Should a statin be given on an LDL-
based treat-to-target goal (as stated in the
guidelines, reduce the LDL below 100
mg%),existenceofothervascularriskfac-
tors, age, or regardless of the measured
cholesterol at predetermined doses (sim-
ilar to current use of aspirin).
The second question is what is the
evidence for the target LDL in secondary
prevention in high-risk diabetic individ-
uals—how aggressive should we be, and
should we limit ourselves to an LDL-
targeted therapy versus a comprehensive
high-dose statin strategy. Again there is
the question of the target LDL versus the
“evidence-based” ﬁxed dose?
These questions are further stressed
by the relatively poor efﬁcacy of other
cholesterol-reducing treatments. In the
Fenoﬁbrate Intervention and Event Low-
ering in Diabetes (FIELD) study, feno-
ﬁbrate failed to reduce the primary
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heart disease death or nonfatal myocar-
dial infarction), although achieving a
signiﬁcant 12% reduction in LDL choles-
terol levels (12). The recently published
ENHANCE(EzetimibeandSimvastatinin
Hypercholesterolemia Enhances Athero-
sclerosis Regression) trial failed to show
additive value of ezetimibe therapy on ca-
rotid and femoral intima-media thickness
inpatientswithfamilialhypercholester-
olemia (although it showed a signiﬁcant
16.5% reduction in LDL levels in the
ezetimibe-treated cohort) (13). Further-
more, among the various lipid measure-
ments, LDL is not the strongest predictor
of cardiovascular disease (10,11), thus
pointing to a possible beneﬁcial effect of
statins, regardless of their cholesterol-
reducing properties.
These beneﬁcial/pleiotropic effects of
statinshavebeensuggestedinvariousdis-
ease processes: statins have been impli-
cated in plaque stabilization (14),
reduction of inﬂammation (as noted by a
reductioninC-reactiveprotein[CRP]lev-
els) (15), reversal of endothelial dysfunc-
tion(16),anddecreasedthrombogenicity
(17). They are thought to result from a
reduction in proinﬂammatory nonsteroi-
dal isoprenoid compounds synthesis
through the inhibition of mevalonic acid
processing by 3-hydroxy-3-methyl-3-
glutaryl CoA (HMG-CoA) reductase (18).
Proof of the importance the pleotropic ef-
fect is suggested by the dissociation be-
tween the immediate beneﬁcial effect of
statins in acute inﬂammatory states such
as acute coronary syndrome and their de-
layed LDL-reducing effect (19).
In this mini-review, we would like to
examinetheevidencethatcurrentlyexists
regardingthequestionsraisedabove,sug-
gest a different interpretation of the exist-
ing clinical trial data, and offer our
viewpoint as to the controversies that ex-
ist in the current ADA guidelines.
PRIMARY PREVENTION: IS
THERE A DIABETIC
INDIVIDUAL WHO SHOULD
NOT GET A STATIN?— Diabetes
is a signiﬁcant cardiovascular risk factor
(conferringathreetimeabsoluteadjusted
risk of CVD death). Furthermore, in indi-
viduals with diabetes, a log linear rela-
tionship exists between cholesterol levels
and CVD regardless of the baseline LDL
(20). Thus, it was assumed, that regard-
less of the baseline cholesterol level, reduc-
ing the LDL will reduce the occurrence of
CVD. This led to a number of primary
cardiovascularpreventiontrialsusingsta-
tin therapy as the principal intervention.
It has been clearly shown (and thus
clearly incorporated into the ADA guide-
lines) that diabetic individuals with other
risk factors should indeed be treated with
a statin (4,5).
Yet only a few studies have included
diabetic individuals without other CVD
risk factors (Table 2). In the Heart Protec-
tion Study (HPS), 5,963 individuals with
diabetes were randomized to 40 mg sim-
vastatin or placebo regardless of their
baselineLDLorpriorvasculardiseasesta-
tus. A signiﬁcant 22% reduction in the
ﬁrst event rate of major vascular out-
comes (ﬁrst major coronary event,
stroke, or revascularization) was noted
(2). Based on the HPS data, an evalua-
tion of the cost-effectiveness of lifetime
simvastatin treatment found it to be cost
saving even in patients as young as 35
years or with a 5-year risk of major vascu-
lar events as low as 5% (considered mod-
erate CVD risk) (21). These criteria
include almost all of the diabetic individ-
uals,includingindividualswithtype1di-
abetes over the age of 30 years (22) and
individuals with type 2 diabetes over the
age of 32 years for men and 38 years for
women (23).
Onthecontrary,therecentAtorvasta-
tin Study for Prevention of Coronary
Heart Disease End Points in non-insulin-
dependent diabetes (ASPEN) failed to
show a signiﬁcant reduction in primary
prevention of major vascular outcomes
(cardiovascular death, nonfatal myo-
cardial infarction, nonfatal stroke, re-
canalization, coronary artery bypass
surgery, resuscitated cardiac arrest, and
worsening or unstable angina requiring
hospitalization) with 10 mg atorvastatin
in patients with type 2 diabetes. This was
partially explained by a short duration
of diabetes in the study population,
changing guidelines necessitating the
addition of lipid-lowering therapy to
26.9% of the placebo group and a low
overall event rate (3).
In the ADA standards of care, a scale
of evidence grade is used (A–E) (Table 1),
where grade “A” evidence refers to evi-
dence from a meta-analysis that incorpo-
rated quality ratings in the analysis. Such
ameta-analysiswasrecentlypublishedby
the Cholesterol Treatment Trialists (CTT)
Collaborators(24).Inthiswork,theeffect
of statin treatment in 18,686 individuals
with diabetes was evaluated from 14 ran-
domizedtrials(inclusioncriteriawereun-
confounded trials with lipid-lowering
primary interventions that aimed to re-
cruitatleast1,000participantswithtreat-
ment duration lasting at least 2 years).
The mean duration of follow-up was 4.3
years.Participantswithdiabeteshada9%
reduction in all-cause mortality per milli-
mole per liter LDL cholesterol reduction
(relative risk 0.91, 99% CI 0.82–1.01;
P  0.02). The overall effect was a con-
sistentreductionof21%inmajorvascular
Table 1—ADA evidence grading system for clinical practice recommendations
A Clear evidence from well-conducted generalizable randomized controlled trials that
are adequately powered, including:
• Evidence from a well-conducted multicenter trial
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre
for Evidence-Based Medicine at Oxford
Supportive evidence from well-conducted randomized controlled trials that are
adequately powered, including:
• Evidence from a well-conducted trial at one or more institutions
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies, including:
• Evidence from a well-conducted prospective cohort study or registry
• Evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies, including:
• Evidence from randomized clinical trials with one or more major or three or more
minor methodological ﬂaws that could invalidate the results
• Evidence from observational studies with high potential for bias (such as case series
with comparison with historical controls)
• Evidence from case series or case reports
D Conﬂicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
Adapted from the American Diabetes Association (1).
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S386 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orgevents per millimole per liter LDL choles-
terol reduction (deﬁned as the composite
outcome of myocardial infarction or cor-
onary death, stroke, or coronary revascu-
larization) (0.79, 99% CI 0.72–0.86; P 
0.0001)(theseresultsdidnotchangedra-
matically after incorporation of the AS-
PEN results; a 20% risk reduction was
calculated). Subgroup analysis revealed
this reduction was consistent irrespective
of whether patients had prior cardiovas-
cular disease, other CVD risk factors (hy-
pertension, smoking, BMI, renal function,
HDL levels), or baseline LDL (up to an LDL
level of 2.6 mmol/l). Thus, even in diabetic
individuals without other cardiovascular
risk factors, a beneﬁcial effect of statins was
noted. This outcome may be a result of the
pleotropic effect of statins, as a different
mechanism of CVD disease reduction, iso-
lated from their LDL-lowering properties.
These studies lead us to reassess the
ADA guidelines for statin use in primary
prevention of CVD. It appears that based
on current available data, all individuals
withdiabetesshouldbetreatedwithastatin
unless they apply to very speciﬁc exclusion
criteria.Thesecriteriaincludeapatientwith
type2diabetesundertheageof32years(or
38 years in women), short duration of dis-
ease(10years),andnoapparentCVDrisk
factors (including a baseline LDL 100
mg%). In individuals with type 1 diabetes,
the age should be even lower, i.e., 30
years of age. To not be prescribed a statin, a
patient will have to have all these exclusion
criteria present (Table 4).
What would the target LDL be in an
individual without prior CVD or CVD
risk factors and a baseline LDL below 100
mg% is yet an unanswered question.
Some data exist as to a goal reduction of
LDL below 70 mg%, as was shown in the
recently published Stop Atherosclerosis
in Native Diabetics Study (SANDS) using
carotid intimal medial thickness as a sur-
rogate marker for CVD progression (25).
Yet,until“hard”majorvasculareventdata
arepublished,wefeelthattheinitialstatin
dose should be ﬁxed and based on pub-
lished clinical trial data (i.e., 10 mg ator-
vastatin or 40 mg simvastatin), thus
changing the current concept of treat-to-
target LDL with statins in this subset of
patients.
SECONDARY PREVENTION:
HOW LOW SHOULD WE
GO? — InpatientswithovertCVD,the
guidelines state an optional goal LDL of
70 mg%. This recommendation is based
on several recently published trials that
examined the effect of aggressive LDL
lowering therapy (i.e., high dose statin
therapy) in high risk populations of pa-
tients(Table3).InthePROVE-ITTIMI22
trial,4,162patients10daysafteranacute
coronarysyndrome(acuteST-segmentel-
evation myocardial infarction [STEMI],
non–ST-segment elevation myocardial
infarction [NSTEMI], or high-risk unsta-
ble angina) were randomized to standard
40mgpravastatintreatmentorhighdose/
aggressive 80 mg atorvastatin treatment
(15). Patients were followed for 18 to 36
months and achieved an average LDL
cholesterol level of 62 mg% in the atorva-
statin group and 95 mg% in the pravasta-
tingroup.Intheaggressivetherapygroup
versus the control group, a signiﬁcant
16% reduction in the primary end point
(a composite of death from any cause,
myocardialinfarction,unstableanginare-
quiring re-hospitalization, revasculariza-
tion and stroke) was noted. 18% of the
1,600 patients in each treatment arm
suffered from diabetes and showed simi-
lar risk reduction to that of the general
cohort. A post hoc analysis of the
PROVE-IT TIMI 22 trial data revealed a
reduction not only in LDL cholesterol but
also in CRP levels. This reduction in CRP
was signiﬁcantly associated with a reduc-
tion in cardiovascular events irrespective
of the associated LDL reduction (26).
Another important trial was the
Treating to New Targets (TNT) study
(27). In one arm of this study, a total of
1,501 patients with diabetes, stable coro-
nary heart disease, and LDL levels 130
mg% were randomized to receive low-
dose (10 mg) or high-dose (80 mg) ator-
vastatin and followed for 4.9 years. At the
end of the study, LDL levels in the low-
dosegroupwere98versus77mg%inthe
high-dose group. This was associated
with a signiﬁcant 25% reduction in the
rate of major cardiovascular events (de-
ﬁned as death from coronary heart dis-
ease, nonfatal non–procedure-related
myocardial infarction, resuscitated car-
diac arrest, or fatal or nonfatal stroke) in
the high-dose versus the low-dose group.
Similar interventions were done in
the A to Z trial and the IDEAL trial. In the
A to Z trial, a little over 2,200 patients
with acute coronary syndrome were ran-
domized to placebo for 4 months and
then 20 mg simvastatin (standard ther-
apy) or aggressively with 40 mg simvasta-
tin for 1 month starting immediately after
enrollment and then increased to 80 mg.
Follow-up was for at least 6 months and
up to 24 months. LDL in the standard
treatmentgroupwasreducedto77versus
63 mg% in the intensive therapy after 8
months of treatment. Although not statis-
tically signiﬁcant, a trend toward a reduc-
tion in the primary outcome (comprising
acompositeofcardiovasculardeath,non-
fatal myocardial infarction, readmission
for acute coronary syndrome, and stroke)
was observed in the intensive treatment
arm (28). In the IDEAL trial, 8,888 pa-
tients after myocardial infarction were
randomizedtoreceivelow-dosesimvasta-
tin (20 mg) or high-dose atorvastatin (80
mg). Again, after a mean follow-up of 4.8
years, the treatment arm failed to show a
superior reduction in the occurrence of
major coronary events but did show a re-
duction in nonfatal acute myocardial in-
farction, coronary revascularization, and
peripheral vascular disease (29). These
were corroborated by several trials exam-
ining surrogate cardiovascular disease
markers such as intimal media thickness
(as previously described) (25) and intra-
vascular ultrasound to measure atheroma
volume progression (14).
None of the clinical outcome trials
were treat-to-target LDL trials. All were
based on a ﬁxed-dose statin algorithm
disregarding the reduction in LDL
achieved. Thus, it would not be wholly
adequate to blame the mere reduction in
LDL for the beneﬁcial effect noted. As
proven by the Pravastatin or Atorvastatin
Evaluation and Infection Therapy
(PROVE-IT TIMI22) trial and others, at
least part of the statin effect can be ana-
lyzed through its reduction of other sur-
rogatemarkerssuchasCRP(26,30,31).A
more prudent evidence-based approach
would support a ﬁxed high-dose atorva-
statin regimen for all diabetic patients
with proven coronary heart disease with
anexclusioncriteriaofaninitialLDLcho-
lesterol 70 mg% (due to lack of evi-
dence) (Table 4).
Currently, trials that try to answer
some of the questions raised above are
under way. The IMPROVE-IT trial [Ex-
amining Outcomes in Subjects With
Acute Coronary Syndrome:Vytorin
(Ezetimibe/Simvastatin) versus Simvasta-
tin], programmed to end by 2011, will
assess the additive value of ezetimibe
therapy to statin therapy, in high-risk pa-
tientspresentingwithacutecoronarysyn-
drome (32). HPS2-THRIVE (Treatment of
HDL to Reduce the Incidence of Vascular
Events) and AIM-HIGH (Athero-thrombo-
sis Intervention in Metabolic syndrome
with low HDL/High triglyceride and Im-
pact on Global Health Outcomes study)
Eldor and Raz
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ing patients with diabetes and docu-
mented vascular disease) and examine a
possible additive effect of a new extend-
ed-release niacin formulation to statin
therapy on “hard” cardiovascular out-
comes (i.e., time to ﬁrst major vascular
event in HPS2-THRIVE and composite of
cardiovascular death, nonfatal myocar-
dial infarction, nonhemorrhagic stroke,
andhospitalizationforhigh-riskacutecor-
onary syndrome with objective evidence of
ischemia in AIM-HIGH), targeting not
only a preliminary reduction in LDL but
also further niacin-induced elevation of
HDL (33,34). A fourth study is the lipid
treatment arm of the ACCORD trial (Ac-
tiontoControlCardiovascularRiskinDi-
abetes) examining whether a combined
change in the atherogenic lipid proﬁle
(i.e., reducing LDL and triglycerides
while elevating HDL) using a combina-
tionofstatinsandﬁbrateswillreducecar-
diovascular outcomes in individuals with
type2diabetesandgoodglycemiccontrol
(33). The JUPITER trial (Justiﬁcation for
the Use of statins in Primary prevention:
an Intervention Trial Evaluating Rosuvas-
tatin) is a statin-based trial that targets in-
dividuals with high CRP levels and initial
low LDL cholesterol levels (LDL choles-
terol 130 mg/dl (3.36 mmol/l) and
high-sensitivity CRP 2 mg/l) in primary
prevention of cardiovascular outcomes
(35,36). The trial was recently stopped
early, after a median follow-up of 1.9
years,duetoasigniﬁcantreductioninthe
primary end point (combined primary
end point of myocardial infarction,
stroke, arterial revascularization, hospi-
talization for unstable angina, or death
from cardiovascular causes) (0.77 and
1.36per100person-yearsoffollow-upin
the rosuvastatin and placebo groups, re-
spectively; hazard ratio for rosuvastatin,
0.56; 95% CI 0.46–0.69; P  0.00001)
(31). Although these trials may shed light
on the additive effects of other lipid-
altering drugs and cardiovascular risk
markers, only the AIM-HIGH is planned
as a treat-to-target trial (using simvastatin
andezetimibetoreachanLDLcholesterol
80mg%,yetthisapproachwillbetaken
in both control and study groups) (37).
Indeed, although common in trials exam-
ining glycemic control, no other treat-to-
target statin trials are expected in the near
future. Furthermore, because of the al-
ready-proven efﬁcacy of statin therapy
and the costliness of such trials, the
chances of future trials planned in this
manner are slim.
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prevention and in the very-high-risk pa-
tients, it seems that statins reduce major
cardiovasculareventsirrespective(atleast
in part) of the baseline and post-therapy
LDL levels achieved. Should statins be
generally prescribed in a ﬁxed-dose man-
ner? We would not go so far as to suggest
that,butindeed,inthediabeticindividual
whose LDL cholesterol is seemingly
within normal limits, this should be con-
sidered. The indication for statin therapy
in diabetic individuals should not rely
solely on LDL levels but on the inherent
cardiovascular risk that accompanies this
disease (even if goal LDL levels are met).
We believe that the standards of care
for individuals with diabetes should mir-
ror the evidence. Replacing a ﬁxed-dose
statin trial scheme with a treat-to-target
LDL guideline is controversial. This in-
herent problem of the current guidelines
should be amended. Evidence based on
“hard” outcome trials of statin use should
guide our treatment goals and consider-
ations, not epidemiologic or extrapolated
LDL-based data.
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